Brevibacterium lipolyticum

Brevibacterium lipolyticum: A Reference Article

Overview and Scope of the Evidence Base

Brevibacterium lipolyticum is a bacterium belonging to the genus Brevibacterium that appears in multi-strain soil-based organism (SBO) dietary supplement formulations. As a standalone subject of dietary supplement science, the evidence base for B. lipolyticum specifically is extremely limited: no published human clinical trials have evaluated this species in isolation, and no independent pharmacological monographs exist for it in major pharmacopeias or among institutional health body databases such as the NIH Office of Dietary Supplements, NCCIH, WHO, or EFSA. All factual claims in this article are derived from peer-reviewed microbiological and clinical literature addressing either the Brevibacterium genus broadly, multi-strain formulations containing B. lipolyticum as one ingredient among many, or the taxonomic and biochemical properties of Brevibacterium species. This narrow evidence base is stated plainly throughout.

Identity and Taxonomy

Taxonomic Classification

Brevibacterium is a genus of Gram-positive, nonmotile, non-spore-forming bacteria in the family Brevibacteriaceae, phylum Actinobacteria, characterized by irregular rod-shaped cells that undergo a distinct rod-to-coccus growth cycle. It is classified within the domain Bacteria, phylum Actinomycetota, class Actinomycetes, order Micrococcales, family Brevibacteriaceae. The genus Brevibacterium was established by Breed (1953), with B. linens as the type species, for a number of Gram-positive, short, unbranching, rod-shaped bacteria formerly classified in the genus Bacterium.

Owing to the poor delimitation of the genus, it soon became a repository for a broad range of organisms with very diverse chemical, biochemical and physiological features. Taxonomic studies, in particular those based on cellular chemical analyses, demonstrated the extreme heterogeneity of the genus and resulted in the reclassification of many Brevibacterium species in other coryneform genera (including Arthrobacter, Aureobacterium, Corynebacterium, Curtobacterium, Exiguobacterium, Microbacterium, Nocardioides, Oerskovia and Rhodococcus).

The name "Brevibacterium lipolyticum" has been used in the literature to describe strains that were at one point accommodated within Pimelobacter simplex, a genus proposed to contain certain LL-diaminopimelic acid-containing coryneform bacteria. This reflects the broad taxonomic instability that has historically plagued the genus. The name Brevibacterium lipolyticum appears in quotation marks in formal nomenclature databases such as the List of Prokaryotic names with Standing in Nomenclature (LPSN), indicating it is not a currently validly published species name according to the bacteriological code. As of 2025, the genus encompasses 41 validly named species.

Morphological and Physiological Characteristics

Brevibacteria are Gram-positive, irregular, slender, rod-shaped bacteria that display a marked rod-to-coccus cycle and are nonacid fast. They are nonmotile, frequently halotolerant, produce catalase and proteinases, and especially produce methanethiol (MTL) from L-methionine.

These strictly aerobic, halotolerant organisms possess a high DNA G+C content (58–71 mol%) and are notable for their ecological roles in food fermentation, particularly cheese ripening, as well as their presence as commensals on human skin and in diverse environmental niches. Morphologically, Brevibacterium species appear as slender, irregular rods measuring 0.6–1.2 μm in width and 1.5–6 μm in length, and they are non-acid-fast and catalase-positive. Physiologically, they thrive in a temperature range of 4–42°C with an optimum of 20–35°C (up to 37°C for human-associated isolates), at pH levels from 5.5 to 9.5, and demonstrate tolerance to high salt concentrations.

Brevibacteria are aerobes, and produce little or no acid from sugar metabolism. They have mainly been isolated from skin, ears and dairy products. Brevibacteriaceae have been isolated from various habitats, such as milk products, poultry, sediment, soil, oil paintings, clinical specimens, multiple sites on the human body, insects, brown algae, and marine environments.

The Species Name "lipolyticum" and Its Meaning

The epithet lipolyticum derives from the Latin and Greek roots meaning "fat-dissolving" or "lipid-cleaving." The bacterial genera with recognized lipolytic (lipase-producing) activity include Acinetobacter sp., Arthrobacter sp., and Brevibacterium sp., among others. Lipases (triacylglycerol acyl hydrolases EC 3.1.1.3) are enzymes that catalyze the hydrolysis of triacylglycerol into glycerol and fatty acids. The species designation thus implies a defining biochemical property: the ability to produce lipase enzymes. No primary source research specific to the lipase of B. lipolyticum in isolation was identified in the peer-reviewed literature.

Natural Sources and Ecological Habitat

The genus shows a heterogeneity in physiological, biochemical, and chemical features, resulting in the delineation of Brevibacterium species that have been isolated from various habitats, such as fermented food (dairy products), animal and human skin, insects, soil (salt lake, marine, and beach sediments), and mural paintings.

Soil-based organisms (SBOs), a category that includes B. lipolyticum in commercial formulations, refer to naturally occurring microorganisms originally derived from healthy soil ecosystems. These species co-evolved with humans through continual contact with the environment, plants, and unprocessed foods. Historically, humans ingested a small number of soil microbes daily through unwashed vegetables, wild herbs, and direct contact with the earth. Modern sanitation and food processing have largely removed this environmental exposure.

Within the Brevibacterium genus more broadly, microbial communities from rinds of surface-ripened cheeses are composed of various bacteria, yeasts and molds. These microorganisms may come from the milk, the ripening environment, or from ripening cultures that are widely used in the cheese industry. Brevibacterium lipolyticum itself has not been individually characterized as a cheese-ripening species in the peer-reviewed scientific literature; this role is primarily described for B. linens, B. aurantiacum, B. antiquum, and B. casei.

Traditional and Historical Use

No traditional medicinal or ethnobotanical record of deliberate human use of Brevibacterium lipolyticum as a health preparation exists in the peer-reviewed literature or in official monographs. The bacterium is not referenced in traditional herbal medicine systems such as Traditional Chinese Medicine, Ayurveda, or European folk medicine. It has no entry in the WHO Traditional Medicine monographs, the German Commission E, ESCOP monographs, or similar historical pharmacopeial sources.

Unlike conventional lactic acid–based probiotics, which are primarily isolated from fermented foods, soil probiotics are resilient environmental strains. Historically, humans ingested soil microbes daily through unwashed vegetables, wild herbs, and direct contact with the earth. The framing of incidental, passive environmental exposure to soil organisms as a precursor to modern SBO supplementation is a contemporary narrative used within the dietary supplement industry rather than a documented historical medicinal tradition.

Brevibacterium lipolyticum appears in the modern dietary supplement era, specifically as one constituent among 29 strains in the soil-based organism probiotic formulation known as Prescript-Assist, commercialized in the 2000s. The probiotic component of this formulation includes 29 soil-based microorganisms (SBOs) that are representative of small, self-regulating ecological units observed during organic-matter breakdowns in soils and sufficient for plant viability in sterilized soils. The prebiotic component, largely leonardite, is a nutritional medium that enhances SBO proliferation.

Key Constituents and Active Compounds

Genus-Level Biochemical Properties Relevant to B. lipolyticum

Because B. lipolyticum has not been individually characterized in detail in the peer-reviewed dietary supplement literature, the following biochemical properties are drawn from the broader genus, chiefly from the well-characterized type species B. linens and related validated species.

Lipases and lipolytic enzymes. Compared to lipases from plants and animals, microbial lipases are increasingly valuable and preferable due to the diverse substrates they use, high yield production, greater stability, shorter generation time, and lower production costs. Microbial lipases as multipurpose biological enzymes are of significant interest for various applications in biological and industrial processes including food and drink, leather, detergents, cosmetics, textiles, agrochemicals, pharmaceutical industries, and waste treatment. The species designation "lipolyticum" indicates lipase-producing capacity. Lipase (EC 3.1.3.1), an enzyme of the class serine hydrolase, plays an important role in the digestion of fats by catalyzing the hydrolysis of triacylglycerol (TAG) into mono- and diacylglycerols and free fatty acids. Aside from hydrolysis, lipase is also capable of catalyzing esterification, trans-esterification, alcoholysis, amidation, acidolysis, and aminolysis in a non-aqueous media.

Methionine catabolism and volatile sulfur compounds. A defining biochemical feature of multiple Brevibacterium species — particularly relevant to understanding the genus as a whole — is the catabolism of methionine to volatile sulfur compounds. L-methionine-γ-demethiolase is the principal enzyme responsible for the production of methanethiol by B. linens. This enzyme catalyses the α,γ-elimination of methionine to produce methanethiol, α-ketobutyrate, and ammonia. Methionine is believed to be the precursor of numerous diverse volatile sulfur compounds (VSCs) which make important contributions to the overall flavor typical of different cheeses. Most of these compounds are derived from the degradation of methionine to methanethiol (MTL), giving rise to a variety of compounds such as dimethyl disulfide (DMDS), dimethyl trisulfide (DMTS), and S-methylthioesters. Whether B. lipolyticum specifically produces this enzymatic pathway is not documented in individually characterized peer-reviewed studies.

Proteases. Some of the distinguishing features of Brevibacterium strains concern biotic interactions such as the secretion of proteases and triacylglycerol lipases, and competition for iron or bacteriocin production.

Pigments. Several Brevibacterium species produce orange-red carotenoid pigments. This microorganism contributes to the breakdown of lipids and proteins, and produces volatile sulfur compounds that are key aroma impact compounds, as well as red-orange pigments. Again, these features are documented for named, validated species within the genus and have not been individually confirmed for B. lipolyticum.

Formulation and Use as a Dietary Supplement

Preparations and Commercial Forms

Brevibacterium lipolyticum is found commercially as a component of multi-strain soil-based organism (SBO) probiotic blends. One such commercially available formulation lists a proprietary blend of 29 probiotic strains including Brevibacterium lipolyticum alongside Arthrobacter, Azotobacter, Bacillus, Bacteroides, Brevibacterium stationis, Pseudomonas, Streptomyces, and other genera.

It is critical to note that B. lipolyticum is never the sole ingredient in any identified commercially available supplement; it is always one member of a multi-strain, multi-genus consortium. No standalone preparation of B. lipolyticum appears in any identified product, monograph, or clinical research protocol reviewed for this article.

Dosage as Reported in Studies

In the only published controlled human clinical trial of the multi-strain formulation (Prescript-Assist) containing B. lipolyticum as a component: patients were randomly assigned to receive either Prescript-Assist one 500-mg capsule BID (twice daily) or one placebo capsule BID for 2 weeks. The dosage pertains to the entire 29-strain blend, not to B. lipolyticum individually. No independently established dose for B. lipolyticum exists in the peer-reviewed literature.

Scientific Evidence by Area of Use

Critical Preliminary Note on Evidence Attribution

All clinical research identified for this section evaluates multi-strain SBO formulations (primarily the Prescript-Assist blend) that contain B. lipolyticum as one of 29 organisms. No human clinical trial, animal study, or in vitro experiment that isolates B. lipolyticum as the independent variable was identified in peer-reviewed databases. Caution must therefore be exercised in attributing any observed clinical effect to B. lipolyticum specifically.

Irritable Bowel Syndrome (IBS)

Study 1 (Randomized Controlled Trial, 2005): The symptomatic efficacy of Prescript-Assist, a treatment combining probiotic and prebiotic components, had previously been evaluated clinically only in an open-label study in patients with various gastrointestinal conditions, including IBS. This study was conducted to compare the effects of Prescript-Assist with placebo in patients with a diagnosis of IBS. A secondary methodological goal was to determine the number and nature of symptom clusters ("subsyndromic factors") that characterize IBS. This was a double-blind, placebo-controlled clinical study in which patients were randomly assigned to receive either Prescript-Assist one 500-mg capsule BID or one placebo capsule BID for 2 weeks. This study identified 3 subsyndromic factors of IBS: general ill feelings/nausea, indigestion/flatulence, and colitis. In this methodologically oriented double-blind study in patients with IBS, combined probiotic-prebiotic treatment with Prescript-Assist was associated with significant reductions in these factors.

Study 2 (Open-Label Extension, 2007): The aim of this study was to extend a previous 2-week assessment of a probiotic-prebiotic complex in patients with IBS. In this open-label, partially controlled, 1-year (14 ± 2 months) extension study, data were collected from patients with IBS who continued treatment following the 2-week study. Data were collected at 2 and approximately 60 weeks after the end of the original study. A total of 25 patients entered the 2-week extension and 22 completed the approximately 60-week follow-up study (20 women, 2 men; age range, 20–70 years; all white). Based on the results from the present 1-year extension study, treatment with this probiotic-prebiotic complex may be an option for short-term (2–4 weeks) and long-term (approximately 60-week) reductions in IBS symptoms.

Evidence Strength Assessment: Evidence is preliminary and weak for attribution to B. lipolyticum specifically. The two published controlled studies evaluated a 29-strain blend and were both conducted by the same research group (Battelle Seattle Research Center). Both peer-reviewed studies were done by Battelle Seattle Research Center, Washington, USA. The randomized trial enrolled a small number of subjects, was of very short duration (2 weeks), and involved a proprietary multi-strain formulation in which the contribution of any individual species — including B. lipolyticum — cannot be isolated. The open-label extension lacks a control arm for the longer follow-up period. No independent replication of these findings by separate research groups has been identified.

Bacterial Diarrhea

Clinical research was conducted to evaluate the efficacy of Prescript-Assist (P-A), an advanced probiotic-prebiotic formulation for treatment of human bacterial diarrhea in two communities in Ecuador. P-A had previously demonstrated efficacy against irritable bowel syndrome and related gastric diseases. In this study, P-A treatment was shown to result in significantly shorter diarrhea durations than standard antibiotics used in treating bacterial diarrhea.

Evidence Strength Assessment: Evidence is preliminary. This finding applies to the full 29-strain formulation, not to B. lipolyticum individually. Methodological details, sample size, and blinding status of this Ecuador study are incompletely reported in the accessible published record. Independent replication has not been identified.

General Gastrointestinal Function

Prescript-Assist is described as a probiotic-prebiotic complex with apparent efficacy for a wide range of gastrointestinal and other disorders. Initially used "to minimize gastritis with/after antibiotics," clinical reports increasingly pointed toward broader applications. Reviews have selectively targeted the validity of observations regarding IBS, colitis, and bacterial diarrhea.

No randomized controlled trials evaluating the effect of B. lipolyticum — or even of the Prescript-Assist formulation as a whole — on colitis, intestinal permeability, gut microbiota composition, or other gastrointestinal endpoints beyond IBS symptoms and bacterial diarrhea were identified in a search of peer-reviewed databases.

Areas Claimed but Not Supported by Peer-Reviewed Evidence

No peer-reviewed clinical or preclinical research was found supporting the use of B. lipolyticum individually, or the multi-strain formulations containing it, for weight management, immune modulation, metabolic health, mental health, or any systemic condition outside of the gastrointestinal tract. Claims circulating in commercial contexts regarding such uses are not supported by the evidence reviewed for this article and are therefore omitted.

Body Systems and Health Areas Associated with the Genus

Brevibacterium species as a group — primarily well-characterized validated species such as B. linens and B. casei — are associated with the following biological contexts based on peer-reviewed literature:

• Gastrointestinal system: The multi-strain formulation containing B. lipolyticum has been evaluated in IBS and bacterial diarrhea (see above).
• Skin microbiome: Brevibacterium species are Gram-positive, non-spore-forming bacteria commonly found in soil, dairy products, and human skin flora.
• Food fermentation and lipid metabolism: This microorganism contributes to the breakdown of lipids and proteins, and produces volatile sulfur compounds that are key aroma impact compounds, as well as red-orange pigments. This biochemical role is documented primarily for cheese-ripening species of the genus and is relevant to understanding the metabolic toolkit of the genus, not to any specific therapeutic effect in humans.
• Infectious disease (opportunistic pathogen context): Several Brevibacterium species have been identified as opportunistic pathogens in clinical case literature (see Safety section below).

Safety Considerations

Opportunistic Pathogenicity in the Genus

The most clinically significant safety consideration regarding Brevibacterium as a genus — relevant to interpreting the risk profile of B. lipolyticum in supplementation — is its documented potential as an opportunistic pathogen in medically vulnerable individuals.

Brevibacterium species had been considered nonvirulent until infections mainly in immunocompromised patients were reported. Brevibacterium has been reported as a rare cause of catheter-related bloodstream infection mainly in immunocompromised hosts such as patients with malignancies or AIDS.

They usually cause opportunistic infections in immunocompromised patients such as those with HIV infection or malignancies. There have been rare cases of infections such as peritonitis, brain abscess, endophthalmitis, pericarditis, and osteomyelitis caused by Brevibacterium species. They are most commonly isolated from blood cultures, and a majority of these are catheter-related bloodstream infections. The most common Brevibacterium species detected in clinical specimens is Brevibacterium casei.

Cases of Brevibacterium bacteremia most often occur as opportunistic pathogens in patients who are immunocompromised, usually due to malignancy or AIDS. Other important risk factors include indwelling foreign materials, prosthetic heart valves, and continuous ambulatory peritoneal catheters for dialysis. There is also an overwhelming correlation between bacteremia by this genus and indwelling central venous catheters, with a central venous catheter being present in 10 out of 11 cases of bacteremia reviewed in one analysis.

These results suggest that Brevibacterium bacteremia could have a poor prognosis. To underestimate these unspecific but relevant clinical symptoms and misinterpret them as apathogenic organisms could contribute to delayed diagnosis and treatment of this emerging and mainly opportunistic pathogen.

Antibiotic susceptibility: Most clinical Brevibacterium isolates have been reported to be susceptible to β-lactams, ciprofloxacin and vancomycin. Of the cases in which bacteremia is associated with indwelling catheters, all were treated with antibiotics for two to three weeks, predominantly with glycopeptides and quinolones, as well as removal of the catheter.

It should be noted that the species associated with these clinical infections are predominantly identified, validated species (B. casei, B. epidermidis, B. paucivorans, B. otitidis). Brevibacterium lipolyticum itself has not been individually reported as a causative agent of infection in the case report literature reviewed. Nevertheless, the genus-level pathogenic potential warrants attention in the context of supplementation.

Strain Identification and Labeling Concerns

Many commercial SBO supplements list only "soil-based organisms" or "proprietary spore blend" without identifying the exact species or strain. This obscures safety verification, as different bacterial species vary greatly in pathogenic potential.

Furthermore, the taxonomic status of "Brevibacterium lipolyticum" is itself uncertain; as noted above, the name appears in formal nomenclature in quotation marks, indicating it does not currently hold valid published status under the International Code of Nomenclature of Prokaryotes. This creates ambiguity about which actual biological strain(s) a given supplement product contains when it lists this name.

Populations of Specific Concern

Brevibacterium species are considered opportunistic pathogens, typically associated with bloodstream infections in immunocompromised individuals. Given this genus-level safety profile, individuals who are immunocompromised (due to malignancy, HIV/AIDS, corticosteroid or immunosuppressive therapy, or organ transplantation) or who have indwelling medical devices represent a population in which the clinical risk-benefit profile of SBO supplementation containing Brevibacterium species has not been formally evaluated. Physicians and microbiologists should be aware that Brevibacteria are uncommon but important agents which could cause opportunistic infections in immunocompetent as well as immunocompromised patients.

Resilience Characteristics and Supplement-Specific Concerns

While soil-based probiotics (SBOs) are marketed as natural and resilient alternatives to conventional probiotic strains, their growing popularity has outpaced regulatory oversight. Independent testing and published case reports highlight several safety and labelling concerns.

Each SBO strain behaves differently, so there is concern that certain species have the ability to invade, adhere to the body, and produce toxic effects. Some opponents also fear that because SBO species are so hardy, it would be very difficult to eliminate them, especially if they were to become pathogenic.

Summary of Evidence Strength

• Taxonomic/microbiological identity: Characterized at genus level; species-level identity of "lipolyticum" is taxonomically uncertain, as it is not a currently validly published species name.
• Biochemical properties (lipase production, protein breakdown): Genus-level evidence, well-established for validated species; species-specific data for B. lipolyticum not found in peer-reviewed literature.
• Clinical evidence for IBS and bacterial diarrhea: Preliminary; limited to small studies of a 29-strain formulation by a single research group; no isolation of B. lipolyticum's individual contribution is possible from existing data.
• Clinical evidence for any other health condition: None identified in peer-reviewed literature for B. lipolyticum specifically or for the multi-strain formulations containing it beyond IBS and diarrhea.
• Safety data specific to B. lipolyticum: Not individually characterized; genus-level safety signals include documented opportunistic infections by related species in immunocompromised and medically vulnerable individuals.

References

• LPSN – List of Prokaryotic names with Standing in Nomenclature: Genus Brevibacterium
• Springer: The Genus Brevibacterium (Prokaryotes reference chapter)
• Springer: The Genus Arthrobacter (coryneform taxonomy context, including Brevibacterium lipolyticum reclassification)
• PMC: Comparative genomic analysis of Brevibacterium strains – cheese habitat adaptation
• ScienceDirect Topics: Brevibacterium – overview
• ScienceDirect Topics: Brevibacterium linens – overview
• Grokipedia: Brevibacterium (taxonomy, physiology)
• SciELO Brazil: Production of lipolytic enzymes by bacteria isolated from biological effluent treatment systems
• PMC: Investigation of Lipolytic-Secreting Bacteria from Artificially Polluted Soil
• PMC: Optimization and characterization of alkaliphilic lipase from Bacillus cereus (lipase biochemistry)
• PubMed: Bittner AC et al. Prescript-Assist probiotic-prebiotic treatment for IBS: RCT. Clin Ther. 2005;27(6):755–61
• PubMed: Bittner AC et al. Prescript-Assist probiotic-prebiotic treatment for IBS: 1-year extension. Clin Ther. 2007;29(6):1153–60
• Academia.edu: Prescript-Assist bacterial diarrhea study (Ecuador)
• ScienceDirect: Aspects of enzymology and biochemical properties of Brevibacterium linens relevant to cheese ripening
• Journal of Dairy Science: Aspects of enzymology and biochemical properties of Brevibacterium linens – review
• PubMed: Catabolism of volatile sulfur compounds precursors by Brevibacterium linens and Geotrichum candidum
• ASM: Heterologous production of methionine-γ-lyase from Brevibacterium linens in Lactococcus lactis
• BMC Infectious Diseases: Brevibacterium paucivorans bacteremia – case report and literature review
• PMC: Brevibacterium species isolated in cerebrospinal fluid – rare case report
• Clinical Microbiology and Infection: Pericardial infection caused by Brevibacterium casei
• PMC: Successful Treatment of Brevibacterium Bacteremia Solely With Antimicrobial Therapy
• Mediterranean Journal of Infection: Infective endocarditis caused by Brevibacterium sanguinis – literature review
• PubMed: Bacteremia caused by Brevibacterium species in an immunocompromised patient
• ScienceDirect: Brevibacterium casei catheter-related bloodstream infection in an immunocompromised patient
• Science.gov: Brevibacterium topics and lipase/esterase activity